Information was received from multiple sources (manufacturer representative, healthcare provider) regarding a patient who was receiving fentanyl (450 mcg/ml at 50mcg/day) and bupivacaine (22,500 mcg/ml at 2500 mcg/day) via an implantable pump for spinal pain indications.It was reported that the patient had loss of therapeutic benefit.There were no known factors that may have contributed to the issue.They were unable to aspirate from cap (catheter access port) chamber.They opened the spinal segment pocket on (b)(6) 2022 and replaced the spinal segment.At that point, they were still unable to aspirate from cap.They opened the pump pocket segment and found no noticeable kinks.The pump segment was replaced and attached in the pump pocket site.They were able to aspirate from the cap successfully.The pump was updated with new catheter lengths.The issue was resolved at the time of report.The patient's medical history was asked but unknown.The patient's status at the time of report was alive - no injury.
|
Concomitant medical products: product id: 8780, serial#: (b)(4), implanted: (b)(6) 2020, explanted: (b)(6) 2022, product type: catheter.The main component of the system.Other relevant device(s) are: product id: 8780, serial/lot #: (b)(4), ubd: 17-aug-2022, udi#: (b)(4).If information is provided in the future, a supplemental report will be issued.
|